John Theurer Cancer Center Researchers to Present 47 Cutting Edge Studies at 2018 ASH Annual Meeting

John Theurer Cancer Center Researchers to Present 47 Cutting Edge Studies at 2018 ASH Annual Meeting

As part of the upcoming American Society of Hematology’s (ASH) 60th annual meeting in San Diego, December 1st through the 4th, experts at Hackensack Meridian Health John Theurer Cancer Center will release 47 studies examining new cancer treatments, ways to predict the best treatment outcomes, and patient quality of life issues.
Among the promising research, John Theurer Cancer Center investigators will present highlights from the following studies:

Abstract Number Type Abstract Name
91 Oral Presentation Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience
207 Oral Presentation Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study
256 Oral Presentation Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematological Malignancies – Cpit-001 Trial
402 Oral Presentation The iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) Is Active with a Manageable Safety Profile in Patients with Relapsed/Refractory Non–Germinal Center-like Diffuse Large B-cell Lymphoma
453 Oral Presentation Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy
488 Oral Presentation Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy
560 Oral Presentation Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation is Safe, Effective, and Leads to MRD-Negative Complete Remissions
614 Oral Presentation Patient Treatment Preferences for Relapsed/Refractory Multiple Myeloma: Are Patients Willing to Trade Off Efficacy for Tolerability?
662 Oral Presentation Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3-ITD–Mutated AML
799 Oral Presentation Carfilzomib-Lenalidomide-Dexamethasone Versus Bortezomib-Lenalidomide-Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Results from the Prospective, Longitudinal, Observational Commpass Study
871 Oral Presentation Aging of the Vascular Niche Enhances Leukemia-Initiating Cell Metabolic Switch
997 Oral Presentation The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas
1001 Oral Presentation The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
1020 Oral Presentation Prospective Analysis of Bortezomib, Fludarabine and Melphalan as Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation for Multiple Myeloma.
1289 Poster Inhibition of Endothelial mTOR Drives Hematopoietic Stem Cell Aging
1290 Poster Endothelial MAPK Activation Disrupts Hematopoiesis By Depleting Plasma Scgf
1388 Poster Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study
1393 Poster Molecular Epidemiologic Associations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Within the United States
1618 Poster Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study
1635 Poster Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing)
1677 Poster Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal Study
1730 Poster Dosing Patterns of Dasatinib Use in SIMPLICITY, an Observational Study in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients (pts) in Routine Clinical Practice.
1963 Poster Efficacy and Safety of Carfilzomib and Dexamethasone in Lenalidomide Exposed and Refractory Multiple Myeloma Patients: Combined Analysis of Carfilzomib Trials
2012 Poster Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab
2131 Poster Elevated IL-1Ra Levels in the Stem Cell Product is Associated with the Development of Engraftment Syndrome Following Autologous Stem Cell Transplantation for the Treatment of Multiple Myeloma and Lymphoma
2154 Poster Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose Melphalan As a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma
2577 Poster Single-Cell Characterization of the HSC-Supportive Bone Marrow Vascular Microenvironment
2703 Poster Blinatumumab Induces Responses in Extramedulary B­Cell Acute Lymphoid Leukemia (B­ALL) and Lymphoid Blast Crisis Chronic Myelogenous Leukemia (CML), and Rarely Results in CD19 Negative Relapse
2876 Poster Long-Term Follow-Up of Acalabrutinib Monotherapy in Patients With Relapsed/Refractory Mantle Cell Lymphoma
2967 Poster 2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma
3142 Poster Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients
3243 Poster Subgroup Analysis of Patients with Biochemical or Symptomatic Relapse at the Time of Enrollment in the Endeavor Study
3254 Poster Carfilzomib Cardiovascular Disease: Use of the Atherosclerotic Cardiovascular Disease Score to Predict Cardiovascular Events In Multiple Myeloma Patients Treated With Carfilzomib
3271 Poster Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure
3277 Poster Once Weekly Versus Twice Weekly Carfilzomib Dosing in Patients with Relapsed and Refractory Multiple Myeloma (A.R.R.O.W.): Efficacy and Safety Analyzed By Age Group
3383 Poster Largest Reported Series of Adults Who Received Treatment with Eculizumab (ECU) for Hematopoietic Cell Transplantation-Associated Thrombotic Microangiopathy (TA-TMA). a Single Center Experience
3421 Poster Evaluation of Treg and Memory T Cell Profiles, Post-ASCT with Early Combination Nivolumab/Ipilimumab Therapy, in Patients with Multiple Myeloma and Diffuse Large B Cell Lymphoma
3443 Poster Influence of gut microbiome on clinical outcomes in a Phase Ib-IIA study of combined checkpoint inhibition after autologous hematopoietic stem cell transplantation in patients at high-risk for post-transplant recurrence CPIT-001 Trial
4144 Poster Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)
4155 Poster Access to Initial Treatment Was Not the Driving Force of the Survival Disparity By Insurance Status in Follicular Lymphoma – an Analysis of the National Cancer Database (NCDB)
4246 Poster Comparison of the Transcriptomic Signature of Pediatric Vs. Adult CML and Normal Bone Marrow Stem Cells
4410 Poster Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Management, and Dosing Patterns in a Large Cohort of Venetoclax Treated CLL Patients in Community and Academic Settings
4452 Poster The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?
4554 Poster Comparison of Peripheral Blood Stem Cell Mobilization for Multiple Myeloma Patients Over 70 years of Age with Younger Patients
4604 Poster Evaluation of T Cell and Monocyte Immune Subsets in the Stem Cell Product of Patients Developing Engraftment Syndrome Following Autologous Stem Cell Transplantation for Multiple Myeloma and Lymphoma
4759 Poster Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno– and Novel Agent–Based Therapy: A Multicenter Study
4799 Poster Adhering to Recommended Lifestyle Changes and Medications 9 Months to 3 Years after Hematopoietic Stem Cell Transplant: Self-Reported Adherence and the Practical, Psychological, and Social Correlates of Adherence

For more information about the ASH conference or the research being presented, go to

Press contact:

Katherine Emmanouilidis
Hackensack Meridian Health
John Theurer Cancer Center
60 2nd Street
Hackensack, NJ 07601
O: 551-996-3764

John Theurer Cancer Center at Hackensack University Medical Center is New Jersey’s largest and most comprehensive center dedicated to the diagnosis, treatment, management, research, screenings, and preventive care as well as survivorship of patients with all types of cancers. The 14 specialized divisions covering the complete spectrum of cancer care have developed a close-knit team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. Each year, more people in the New Jersey/New York metropolitan area turn to John Theurer Cancer Center for cancer care than to any other facility in New Jersey. Housed within a 775-bed not-for-profit teaching, tertiary care, and research hospital, John Theurer Cancer Center provides state-of-the-art technological advances, compassionate care, research innovations, medical expertise, and a full range of aftercare services that distinguish John Theurer Cancer Center from other facilities. For additional information, please visit